Hikma Pharmaceuticals Plc ADR HKMPY

$43.08 +0.94 (2.23%)

Valuation

Market cap
—
Revenue TTM
$0
Net income TTM
$0
PE ratio
—
Forward PE
—
Profit margin
0.00%
Debt to equity
—

Trading

Volume
300
Avg volume
5,260
Day's range
$43.08 – $43.08
Shares out
—
Stochastic %K
30%
Beta
—
Analysts
Strong Buy
Price target
—

Price

Company profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital mar...

Show more

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, specialty, and branded pharmaceutical products. The company operates through three segments: Injectables, Hikma Rx, and Branded. The Injectables segment provides generic and specialty injectable products primarily for use in hospitals. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The Hikma Rx segment offers oral, respiratory, and other generic and specialty products for the retail market. It provides its products in various therapeutic areas, including respiratory, oncology, and pain management. The company also offers its products in solid, semi-solid, liquid, and injectable dosage forms. It operates in the United Kingdom, Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, United Kingdom.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
Phone
44 20 7399 2760
Website
https://www.hikma.com
Address
10 Portman Square, London, United Kingdom

Latest news

No headlines yet.